Price
$82.35-8.68%Social Signal Score
Analyst Ratings
37 analystsRevenue
$763.72M+403.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Keith W. Pfeil
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 6,000
- Beta
- 0.96
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 9.34
Financials
Revenue
$763.72M+403.8%Net Income
$141.17M+481.0%EBITDA
$253.64M+382.7%Free Cash Flow
$224.84M+496.6%EPS (diluted)
$1.04+316.0%Shares Outstanding (diluted)
136.02M+40.9%Operating Expenses
$323.00MCash & Debt
$517.43MReturn of Capital
$142.94MRevenue by Segment (annual)
$2.52BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.94B | $537.90M | $3.98 |
| 2024 | $2.52B | $102.98M | $0.76 |
| 2023 | $1.57B | $122.87M | $1.09 |
| 2022 | $1.02B | $190.17M | $1.89 |
| 2021 | $958.10M | $149.19M | $1.48 |
| 2020 | $789.04M | $102.28M | $1.04 |
| 2019 | $785.37M | $155.21M | $1.57 |
| 2018 | $712.97M | $156.47M | $1.60 |
| 2017 | $635.98M | $107.35M | $1.12 |
| 2016 | $563.99M | $104.34M | $1.09 |
| 2015 | $544.75M | $112.78M | $1.19 |
| 2014 | $474.37M | $92.48M | $0.98 |
| 2013 | $434.46M | $68.61M | $0.74 |
| 2012 | $385.99M | $73.83M | $0.82 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GMED's reported EPS growth of 12.9% a year over 13 years.
- EPS in 5 years
- $7.30
- Implied price
- $160.61
- Return from $71.27
- 17.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $79.85 — today's price is already 10.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| 2.9% | 0.6% | 4.1% | 7.2% | 10.0% | 12.5% |
| 7.9% | 5.5% | 9.2% | 12.4% | 15.3% | 18.0% |
| 12.9% | 10.4% | 14.2% | 17.6% | 20.7% | 23.5% |
| 17.9% | 15.3% | 19.3% | 22.9% | 26.0% | 28.9% |
| 22.9% | 20.2% | 24.4% | 28.1% | 31.4% | 34.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+133.33%Social Signal Score
Mentions (39)
- Newsseekingalpha.com·4d ago·Positive
Globus Medical, Inc. (GMED) Presents at Jefferies Global Healthcare Conference 2026 Transcript Globus Medical, Inc. (GMED) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·15d ago·Negative
Globus Medical Q3 Earnings Call Highlights Globus Medical NYSE: GMED lowered its 2026 revenue forecast after third-quarter sales fell, citing continued declines at its Nevro business, delayed spine product launches and lower contributions from competitive sales recruiting.
View source ↗ - Newszacks.com·16d ago·Negative
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset Globus Medical cuts its 2026 revenue outlook amid spine launch delays and weak Nevro sales while shifting its focus to new products and growth opportunities in 2027.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Globus Medical, Inc. (GMED) Q3 2026 Earnings Call Transcript Globus Medical, Inc. (GMED) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·17d ago·Positive
Globus Medical (GMED) Q3 Earnings Top Estimates Globus Medical (GMED) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.18 per share a year ago.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
View source ↗ - News (Marketaux)seekingalpha.com·20d ago·Neutral
Globus Medical: The Shrinking Robot Line Hides A Growing Annuity (NYSE:GMED) There have been two recent headlines abo[+193 characters]
View source ↗ - Newszacks.com·20d ago·Positive
GMED vs. AXGN: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newszacks.com·20d ago·Neutral
Wall Street Analysts Think Globus Medical (GMED) Could Surge 30.52%: Read This Before Placing a Bet The consensus price target hints at a 30.5% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·20d ago·Positive
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·24d ago·Positive
2 Healthcare Technology Stocks for a Digital Health Boom GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
View source ↗ - Newszacks.com·37d ago·Neutral
GMED or AXGN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newsglobenewswire.com·39d ago·Positive
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the 41st Annual North American Spine Society (NASS) Meeting in San Antonio, Texas, from October 14-17.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
Globus Medical Schedules Third Quarter Earnings Release and Conference Call AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after the market close on Thursday, November 5, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
View source ↗ - Newszacks.com·46d ago·Positive
Reasons to Add Globus Medical Stock to Your Portfolio Now GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
View source ↗ - Newszacks.com·47d ago·Neutral
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.
View source ↗ - Newszacks.com·48d ago·Positive
Here's Why Globus Medical (GMED) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·48d ago·Neutral
3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.
View source ↗ - Newszacks.com·53d ago·Neutral
GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Top Los Angeles Spine Surgeon Dr. Albert Wong Served as Faculty Leader at Advanced Spine Surgery Cadaver Training Courses for SeaSpine and Globus Renowned neurosurgeon Dr. Albert Wong of DOCS Health served as faculty leader at two hands-on cadaver training courses in 2026, teaching minimally invasive
View source ↗ - Newszacks.com·67d ago·Positive
What Makes Globus Medical (GMED) a New Strong Buy Stock Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·74d ago·Neutral
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
View source ↗ - News (RSS)economictimes·77d ago·Positive
Dividend stocks: Kalyan Jewellers, IREDA among over 150 stocks turning ex-record date this week. Do you own any? More than 150 companies, including Kalyan Jewellers, IREDA, Zee Entertainment Enterprises, NSDL and others have scheduled record dates for dividends during the week of September 7 (Monday) to September 11 (Friday).To be eligible for these corporate actions, investors must hold the shares in their demat accounts as of the respective record dates. The list is tentative, as more companie
View source ↗ - Newsprnewswire.com·79d ago·Neutral
YSL BEAUTY IST WIEDER DA - DIE „BLOCK PARTY"-SERIE KOMMT NACH LONDON /PRNewswire/ -- Nach dem gefeierten Auftakt in Madrid und einer Reihe bahnbrechender Veranstaltungen rund um den Globus ist YSL Beauty nun mit der mit Spannung
View source ↗ - News (RSS)investing·80d ago·Neutral
Globus Medical receives CE mark for Excelsius3D imaging system
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
View source ↗ - Newszacks.com·81d ago·Positive
3 Reasons Growth Investors Will Love Globus Medical (GMED) Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newszacks.com·86d ago·Positive
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newszacks.com·87d ago·Neutral
GMED or ITGR: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Integer (ITGR). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·87d ago·Positive
Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsglobenewswire.com·88d ago·Negative
…Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape …
View source ↗ - News (Marketaux)seekingalpha.com·95d ago·Neutral
Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED) Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED)
View source ↗ - Newsseekingalpha.com·95d ago·Positive
Globus Medical: 7 Quarters Of Margin Expansion, Priced For None Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. GMED's base business is compounding faster than headline growth, with international sales rising 18% and gross margin expanding by 200bps, excluding accounting effects. SG&A leverage drove operating margin improvement, while integration of Nevro remains a known, sized, and management-dated drag.
View source ↗ - Newszacks.com·97d ago·Positive
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - Newszacks.com·103d ago·Positive
Globus Medical (GMED) Upgraded to Strong Buy: Here's Why Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·103d ago·Neutral
GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?
View source ↗ - News (Marketaux)insidermonkey.com·105d ago·Neutral
Q2 Earnings Blowouts: 37 Stock That Beat Expectations Globus Medical, In[+341 characters]
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Globus Medical Q2 Earnings Call Highlights Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $1.30 per share
Typical surprise +20.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.23 vs $1.20beat
- Thu, Aug 6$1.34 vs $1.10beat
- Thu, May 7$1.12 vs $0.92beat
- Tue, Feb 24$1.28 vs $1.06beat
- Thu, Nov 6$1.18 vs $0.78beat
- Thu, Aug 7$0.86 vs $0.76beat
Estimates and results for GMED via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GMED officers and directors.
- Bought
- —
- Sold
- $23.4m
0 trades
20 trades
- Tobin James Rsold
- Tobin James Rsold
- Rhoads Ann Dsold
- Tobin James Rsold
- Zarrilli Stephen Tsold
- Davidar David Dsold
- Huller Kellysold
- Huller Kellysold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (39d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (23d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 19, 2023 (46d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 17, 2023 (37d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 17, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 7, 2022 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (13d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2020 (18d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Sep 16, 2019 (52d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
